Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammatory bowel disease
Biotech
Ensho emerges with phase 2-ready asset from Eisai unit
Ensho has unveiled with an inflammatory disease therapy portfolio from Eisai’s EA Pharma, including a phase 2-ready program in ulcerative colitis.
Gabrielle Masson
Jun 28, 2024 11:10am
AbbVie turns up the M&A heat with $250M Celsius buy
Jun 27, 2024 11:00am
AbbVie pays $150M for preclinical IBD drug to join TL1A race
Jun 13, 2024 9:45am
Palisade's ulcerative colitis drug prevents symptoms in mice
May 23, 2024 4:30am
Prometheus team returns with brand-new biotech and $400M
Mar 21, 2024 7:00am
Surrozen stops IBD program due to dose concerns and competition
Jan 18, 2024 9:55am
